+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biologics Contract Development - Global Strategic Business Report

  • PDF Icon

    Report

  • 172 Pages
  • June 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6071250
Description Jump to:
The global market for Biologics Contract Development was estimated at US$9.1 Billion in 2024 and is projected to reach US$14.0 Billion by 2030, growing at a CAGR of 7.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Biologics Contract Development market.

Global Biologics Contract Development Market - Key Trends & Drivers Summarized

Why Is Biologics Contract Development Gaining Momentum in the Biopharmaceutical Industry?

Biologics contract development has become an essential part of the pharmaceutical ecosystem, enabling biotech firms and large pharmaceutical companies to accelerate drug discovery, streamline product development, and optimize manufacturing processes. With the increasing complexity of biologic drugs such as monoclonal antibodies, gene therapies, and recombinant proteins, companies are increasingly outsourcing key stages of biologics development to specialized contract development organizations (CDOs) that offer expertise, regulatory compliance, and advanced manufacturing capabilities. The demand for biologics is surging due to their effectiveness in treating chronic diseases such as cancer, autoimmune disorders, and rare genetic conditions. However, the high costs and technical complexities associated with biologic drug development pose significant challenges for in-house research and development teams. As a result, pharmaceutical companies are leveraging the expertise of CDOs to conduct early-stage research, cell line development, process optimization, and analytical testing, thereby reducing costs and accelerating time-to-market. With the rise of biosimilars and personalized medicine, the need for efficient contract development services is expected to grow substantially in the coming years.

How Are Technological Advancements Enhancing Biologics Contract Development?

The integration of cutting-edge technologies such as artificial intelligence (AI), automation, and single-use bioprocessing systems is transforming biologics contract development, improving efficiency, scalability, and quality assurance. AI-driven drug discovery platforms are enabling faster identification of therapeutic candidates by analyzing vast datasets and predicting molecular interactions with high accuracy. This accelerates the initial stages of biologic development and reduces the time required for preclinical research. Additionally, the adoption of single-use bioreactors and modular production facilities is enhancing the flexibility and cost-effectiveness of biologic manufacturing. These innovations allow contract development organizations to quickly adapt to changing client requirements and improve production efficiency for small-batch and personalized biologic drugs. Moreover, advancements in cell line engineering and gene editing techniques such as CRISPR are improving the productivity and stability of biologic drug candidates, ensuring higher yields and improved therapeutic efficacy. As biologic therapies become more specialized and complex, technological innovation will continue to drive the evolution of contract development services.

What Market Trends Are Driving the Growth of Biologics Contract Development?

One of the most significant trends shaping the biologics contract development market is the increasing demand for biosimilars and novel biologic therapies. As patents for blockbuster biologics expire, pharmaceutical companies are focusing on developing biosimilars to capture market share and provide more affordable treatment options. Contract development organizations play a crucial role in facilitating biosimilar development by providing expertise in analytical characterization, bioequivalence testing, and regulatory compliance. Another key trend is the shift toward personalized medicine and cell and gene therapy development. With advancements in genomic research and precision medicine, pharmaceutical companies are investing in biologic therapies tailored to individual patients. This shift is driving the demand for contract development services that specialize in advanced cell therapies, viral vector production, and customized biologic formulations. Additionally, regulatory agencies are introducing streamlined approval pathways for innovative biologics, encouraging companies to accelerate their development timelines through strategic outsourcing partnerships with contract development organizations.

What Are the Key Growth Drivers for the Biologics Contract Development Market?

The growth in the Biologics Contract Development market is driven by several factors, including increasing demand for biologic drugs, rising investment in biosimilars, and the growing complexity of biologic manufacturing. As pharmaceutical companies seek to optimize costs and accelerate drug development timelines, contract development organizations are playing an increasingly critical role in the industry. The expansion of biologics manufacturing infrastructure, particularly in emerging markets, is further propelling market growth by providing cost-effective development solutions to biotech firms and small pharmaceutical companies. Additionally, the increasing adoption of automation, AI, and advanced bioprocessing technologies is enhancing the efficiency and scalability of biologics contract development services. As regulatory agencies continue to support the expansion of biologics and biosimilars, contract development organizations are expected to see sustained growth, reinforcing their position as key partners in the future of biopharmaceutical innovation.

Scope of Study:

The report analyzes the Biologics Contract Development market in terms of units by the following Segments, and Geographic Regions/Countries:
  • Segments: Source (Mammalian Source, Microbial Source, Other Sources); Service (Process Development Service, Cell Line Development Service, Other Services); Indication (Oncology Indication, Immunological Disorders Indication, Cardiovascular Disorders Indication, Hematological Disorders Indication, Other Indications)
  • Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Mammalian Source segment, which is expected to reach US$6.6 Billion by 2030 with a CAGR of a 7.2%. The Microbial Source segment is also set to grow at 7.0% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $2.4 Billion in 2024, and China, forecasted to grow at an impressive 7.3% CAGR to reach $2.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Biologics Contract Development Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Biologics Contract Development Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Biologics Contract Development Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as Biovian Oy, Boehringer Ingelheim International GmbH, Catalent, Inc., Celonic AG, Charles River Laboratories and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 36 companies featured in this Biologics Contract Development market report include:

  • Biovian Oy
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Celonic AG
  • Charles River Laboratories
  • FUJIFILM Corporation
  • Kemwell Biopharma Pvt. Ltd.
  • Lonza Group
  • LOTTE BIOLOGICS
  • Mabxience Holding S.L.
  • Polymun Scientific Immunbiologische Forschung GmbH
  • Samsung Biologics Co., Ltd.
  • Scorpius BioManufacturing
  • Syngene International Ltd.
  • WuXi Biologics

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

  • Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
  • Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
  • Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
  • Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
  • Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
  • Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
  • Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
Biologics Contract Development - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rapid Expansion of Biopharmaceutical Pipelines Throws the Spotlight on Outsourced Biologics Development Services
OEM Investment in Monoclonal Antibodies, ADCs, and Fusion Proteins Drives Demand for Specialized CDMO Expertise
Surge in Venture Capital Funding for Biotech Startups Propels Early-Stage Biologics Development Outsourcing
Increased Complexity of Biologics Manufacturing Strengthens Business Case for End-to-End CDMO Partnerships
Rising Adoption of Cell and Gene Therapies Spurs CDMO Capability Expansion in Viral Vector and Plasmid Development
OEM Focus on Modular and Flexible Development Platforms Enhances Speed-to-IND and Speed-to-BLA Timelines
Growth in Biosimilars and Biobetters Development Expands Demand for Regulatory-Compliant Development Support
Regulatory Emphasis on CMC Documentation and QbD Principles Drives Demand for Early Integration Services
Shift Toward Integrated Drug Discovery to Manufacturing Models Fuels Strategic CDMO Consolidation
Emergence of Continuous Bioprocessing and PAT Integration Spurs Innovation in Process Development Offerings
OEM Collaboration With CROs and AI Platforms Enhances Data-Driven Molecule Optimization
Surging Interest in Dual-Target and Bispecific Biologics Supports Demand for High-Throughput Screening Platforms
Globalization of Biotech Innovation Clusters Promotes Cross-Border Development Partnerships
OEM Development of Standardized, Platform-Based Expression Systems Supports Scalability and IP Protection
Increased Investment in High-Yield Cell Line Development Services Propels Productivity Optimization
Emphasis on Speed, Cost Containment, and Risk Sharing Drives Growth of Hybrid FFS/FTE Development Models
Demand for Clinical-Grade and Preclinical Material Supply Accelerates Multi-Site Development Capacity Expansion
Expansion of Biologics in Rare Disease and Orphan Drug Portfolios Fuels Need for Flexible CDMO Capabilities
Growth in Personalized Biologics and Companion Diagnostics Enhances Demand for Integrated Development Services
Regulatory Convergence in Global Markets Promotes Use of CDMOs for Multi-Jurisdiction Filing Preparation
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Biologics Contract Development Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Biologics Contract Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World 6-Year Perspective for Biologics Contract Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for Mammalian Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 5: World 6-Year Perspective for Mammalian Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 6: World Recent Past, Current & Future Analysis for Microbial Source by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 7: World 6-Year Perspective for Microbial Source by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Other Sources by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World 6-Year Perspective for Other Sources by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Process Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 11: World 6-Year Perspective for Process Development Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 12: World Recent Past, Current & Future Analysis for Cell Line Development Service by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 13: World 6-Year Perspective for Cell Line Development Service by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Other Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World 6-Year Perspective for Other Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Oncology Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 17: World 6-Year Perspective for Oncology Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 18: World Recent Past, Current & Future Analysis for Immunological Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 19: World 6-Year Perspective for Immunological Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Cardiovascular Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World 6-Year Perspective for Cardiovascular Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 22: World Recent Past, Current & Future Analysis for Hematological Disorders Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 23: World 6-Year Perspective for Hematological Disorders Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 24: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 25: World 6-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 26: USA Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: USA 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
TABLE 28: USA Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 29: USA 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
TABLE 30: USA Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 31: USA 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
CANADA
TABLE 32: Canada Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: Canada 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
TABLE 34: Canada Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 35: Canada 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
TABLE 36: Canada Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 37: Canada 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
JAPAN
Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 38: Japan Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: Japan 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
TABLE 40: Japan Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 41: Japan 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
TABLE 42: Japan Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 43: Japan 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
CHINA
Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 44: China Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: China 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
TABLE 46: China Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 47: China 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
TABLE 48: China Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 49: China 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
EUROPE
Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 50: Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 51: Europe 6-Year Perspective for Biologics Contract Development by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
TABLE 52: Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 53: Europe 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
TABLE 54: Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 55: Europe 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
TABLE 56: Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Europe 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
FRANCE
Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 58: France Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 59: France 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
TABLE 60: France Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 61: France 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
TABLE 62: France Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: France 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
GERMANY
Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 64: Germany Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 65: Germany 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
TABLE 66: Germany Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 67: Germany 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
TABLE 68: Germany Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Germany 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
ITALY
TABLE 70: Italy Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 71: Italy 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
TABLE 72: Italy Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 73: Italy 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
TABLE 74: Italy Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Italy 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
UNITED KINGDOM
Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 76: UK Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 77: UK 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
TABLE 78: UK Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 79: UK 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
TABLE 80: UK Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: UK 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
REST OF EUROPE
TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 83: Rest of Europe 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 85: Rest of Europe 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Rest of Europe 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
ASIA-PACIFIC
Biologics Contract Development Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 89: Asia-Pacific 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 91: Asia-Pacific 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Asia-Pacific 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
REST OF WORLD
TABLE 94: Rest of World Recent Past, Current & Future Analysis for Biologics Contract Development by Source - Mammalian Source, Microbial Source and Other Sources - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 95: Rest of World 6-Year Perspective for Biologics Contract Development by Source - Percentage Breakdown of Value Sales for Mammalian Source, Microbial Source and Other Sources for the Years 2025 & 2030
TABLE 96: Rest of World Recent Past, Current & Future Analysis for Biologics Contract Development by Service - Process Development Service, Cell Line Development Service and Other Services - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 97: Rest of World 6-Year Perspective for Biologics Contract Development by Service - Percentage Breakdown of Value Sales for Process Development Service, Cell Line Development Service and Other Services for the Years 2025 & 2030
TABLE 98: Rest of World Recent Past, Current & Future Analysis for Biologics Contract Development by Indication - Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Rest of World 6-Year Perspective for Biologics Contract Development by Indication - Percentage Breakdown of Value Sales for Hematological Disorders Indication, Other Indications, Oncology Indication, Immunological Disorders Indication and Cardiovascular Disorders Indication for the Years 2025 & 2030
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Biovian Oy
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • Celonic AG
  • Charles River Laboratories
  • FUJIFILM Corporation
  • Kemwell Biopharma Pvt. Ltd.
  • Lonza Group
  • LOTTE BIOLOGICS
  • Mabxience Holding S.L.
  • Polymun Scientific Immunbiologische Forschung GmbH
  • Samsung Biologics Co., Ltd.
  • Scorpius BioManufacturing
  • Syngene International Ltd.
  • WuXi Biologics

Table Information

Report AttributeDetails
No. of Pages172
PublishedJune 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 9.1 Billion
Forecasted Market Value ( USD ) by 2030 $ 14 Billion
Compound Annual Growth Rate7.5%
Regions CoveredGlobal

Related Topics

Related Reports

Biologics Contract Development Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Biologics Contract Development Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Biologics Contract Development Market Report 2025 - Product Image

Biologics Contract Development Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Biologics CDMO Market - A Global and Regional Analysis: Focus on Cell Type, Indication, Molecule Type, and Region - Analysis and Forecast, 2025-2035 - Product Image

Biologics CDMO Market - A Global and Regional Analysis: Focus on Cell Type, Indication, Molecule Type, and Region - Analysis and Forecast, 2025-2035

  • Report
  • 120 Pages
  • Global
From
Biologics Contract Development Market by Service Type, Molecule Type, Therapeutic Area, Host System, End User, Technology - Global Forecast to 2030 - Product Image

Biologics Contract Development Market by Service Type, Molecule Type, Therapeutic Area, Host System, End User, Technology - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
Biologics Contract Manufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size and Key Geographical Regions - Product Image

Biologics Contract Manufacturing Market Industry Trends and Global Forecasts to 2035, by Type of Service Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size and Key Geographical Regions

  • Report
  • 799 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.
OSZAR »